SML0074
醋硝香豆素
≥98% (HPLC)
别名:
(±)-Acenocoumarin, 3-(α-Acetonyl-p-nitrobenzyl)-4-hydroxy-coumarin
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H15NO6
化学文摘社编号:
分子量:
353.33
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
205-807-3
MDL number:
产品名称
醋硝香豆素, ≥98% (HPLC)
InChI key
VABCILAOYCMVPS-UHFFFAOYSA-N
InChI
1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3
SMILES string
CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)C2=C(O)c3ccccc3OC2=O
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO, heptane and xylene: ≥17 mg/mL
originator
Novartis
storage temp.
−20°C
Quality Level
Gene Information
human ... VKORC1(79001)
正在寻找类似产品? 访问 产品对比指南
相关类别
Application
Acenocoumarol has been used as a standard for the determination of coumarins in cosmetics.
Acenocoumarol was used to study the role of P-glycoprotein in transport of oral vitamin K in Caco-2 cells and as an LC/MS standard.
Biochem/physiol Actions
Acenocoumarol is a warfarin analog, an anticoagulant that inhibits Vitamin K epoxide reductase. This results in depletion of the reduced form of vitamin K (vitamin KH2), limiting the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S, resulting in decreased prothrombin levels and the amount of thrombin generated.
Acenocoumarol is effective against thromboembolic disorders.
Warfarin analog; anticoagulant; inhibitor of Vit K epoxide reductase
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Antonio J Carcas et al.
Trials, 13, 239-239 (2012-12-15)
Hemorrhagic events are frequent in patients on treatment with antivitamin-K oral anticoagulants due to their narrow therapeutic margin. Studies performed with acenocoumarol have shown the relationship between demographic, clinical and genotypic variants and the response to these drugs. Once the
Liliane Gschwind et al.
Basic & clinical pharmacology & toxicology, 113(4), 259-265 (2013-05-15)
Vitamin K antagonists (VKAs) are prescribed worldwide and remain the oral anticoagulant of choice. These drugs are characterized by a narrow therapeutic index and a large inter- and intra-individual variability. P-glycoprotein could contribute to this variability. The aim of this
L Gschwind et al.
European journal of clinical pharmacology, 69(3), 617-627 (2012-08-21)
The objective of this study was to identify the most clinically relevant drug-drug interactions (DDIs) at risk of affecting acenocoumarol safety in our tertiary care university hospital, a 2,000 bed institution. We identified DDIs occurring with acenocoumarol by combining two
Juan J Cerezo-Manchado et al.
Thrombosis and haemostasis, 109(1), 146-153 (2012-12-01)
Acenocoumarol is a commonly prescribed anticoagulant drug for the prophylaxis and treatment of venous and arterial thromboembolic disorders in several countries. In counterpart of warfarin, there is scarce information about pharmacogenetic algorithms for steady acenocoumarol dose estimation. The aim of
Saurabh Singh Rathore et al.
PloS one, 7(5), e37844-e37844 (2012-05-26)
To develop a population specific pharmacogenetic acenocoumarol dosing algorithm for north Indian patients and show its efficiency in dosage prediction. Multiple and linear stepwise regression analyses were used to include age, sex, height, weight, body surface area, smoking status, VKORC1
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持